PMD Psychemedics: Forward P/S Multiple

Psychemedics (PMD) - corporate logo

The drug hair analysis market has reached maturity, forcing Psychemedics to expand into the educational sector. An impeccable reputation in occupational health and safety establishes the company as an industry benchmark. The forward P/S multiple reflects market revenue expectations, and its current level is 0.80. Synergy with government agencies and corporations through joint testing projects strengthens the brand's position.

psychemedics.com - PMD Forward Price to Sales (period 07/04/2022 - 12/21/2024)

Summary analytical data breakdowns for Psychemedics Inc (PMD)

- stock price and consensus target price:
Stock Quotes Psychemedics Corporation|PMD - Average Forecast Price
- company stock capitalization data:
Market Capitalization Psychemedics Inc|PMD - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Psychemedics|PMD - Accounting Value of Company|Market Capitalization to Book Value Ratio psychemedics.com|PMD - Company Assets
- debt level and financial liquidity data:
Debt to Equity Psychemedics|PMD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Psychemedics|PMD - Company Cumulative Debt|Debts to Book Capitalization Psychemedics Inc|PMD - Company Long-Term Indebtedness|Company Short-Term Debts Psychemedics|Quick Ratio psychemedics.com
- financial results and valuation multiples details:
PMD - Net Income|Expected Profit Psychemedics|PMD - Business Payback Period|Future Price to Earnings Psychemedics Corp|PMD - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Psychemedics Inc|PMD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Psychemedics|PMD - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months psychemedics.com|PMD - Net earnings per share growth this year|Earnings growth forecast for next year Psychemedics
- company sales and revenue statistics:
PMD - Company Total Revenue|Projected Sales Volume Psychemedics Corporation|PMD - Market Cap to Revenue Ratio|Forward P/S Multiple Psychemedics Inc
Initial company analysis:Psychemedics Corporation PMD
Original product of Psychemedics Inc

The forward P/S ratio determines the relationship between market capitalization and expected sales volume, allowing for an assessment of the asset's overvaluation relative to future cash flows. The current value of 0.80 based on the forward P/S valuation reflects the resilience of Psychemedics (PMD) to cost inflation, which is supported by inelastic demand for mandatory compliance testing and stable free cash flow generation.

Competitor analysis for Psychemedics

Agilent - Forward Price-to-Revenue Multiple|Quest Diagnostics Inc. (DGX) - Market Cap to Future Revenue Ratio|Illumina Corp - Forward P/S Multiple|Exact Sciences Inc. (EXAS) - Forward Price-to-Revenue Multiple|RVTY: Forward P/S Multiple|bio-rad.com - Forward Price to Sales|NNNN (Anbio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Sotera Health Corp SHC|Price-to-Projected Revenue Ratio QuidelOrtho Corp (QDEL)|Forward Price-to-Revenue Multiple OPKO Health Corp. OPK|Forward P/S Multiple CDNA (CareDx, Inc)|maravai.com (MRVI) - Market Cap to Future Revenue Ratio|Fulgent Genetics - Forward P/S Multiple|LAB (Standard BioTools Inc) - Market Cap to Projected Revenue|CTKB: Forward P/S Multiple|OSUR - Market Cap to Expected Sales Ratio|XGN (Exagen Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple mdxhealth.com (MDXH)|Price-to-Projected Revenue Ratio Lucid Diagnostics (LUCD)|Market Cap to Expected Sales Ratio prenetics.com|Price-to-Projected Revenue Ratio Insight Molecular Diagnostics Inc IMDX|TRIB (Trinity Biotech PLC) - Future Price to Revenue|PRPH - Price-to-Projected Revenue Ratio|ainos.com (AIMD) - Forward Price-to-Revenue Multiple|CODX: Forward P/S Multiple|Market Cap to Projected Revenue HSCS|Price-to-Projected Revenue Ratio Biomerica, Inc|Forward Price-to-Revenue Multiple Cardio Diagnostics Holdings, Inc. (CDIO)|Forward P/S Multiple ONCO|VRAX - Market Cap to Future Revenue Ratio|Forward P/S Multiple BJDX (Bluejay Diagnostics, Inc.)|AWH: Market Cap to Projected Revenue|Accelerate Diagnostics, Inc - Forward P/S Multiple|CNTG - Forward P/S Multiple|enzo.com (ENZ) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue FRES|GENE (Genetic Technologies Ltd) - Forward P/S Multiple|Forward P/S Multiple 23andMe Holding Co